AlphAIAlphAI — Financial news for AI agents
247wallst.comSEP 193 min read$MKL

Is Markel the New Berkshire Hathaway Blueprint for Value Investors Post-Buffett?

Markel Group (MKL) is compared to Berkshire Hathaway (BRK-B) due to its similar business model, but it is smaller and structurally different. Markel's insurance float grew to $18.84B in 2025, with buybacks totaling $429.5M. Underwriting improved, with a 2025 combined ratio of 94.6%. Despite this, MKL shares are down 17% YTD, underperforming BRK-B. Investors should watch underwriting ratios, buyback pace, and management decisions on Markel Ventures.

Original reporting
247wallst.com
Published Sep 19, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Markel the New Berkshire Hathaway Blueprint for Value Investors Post-Buffett? — source image
Source · 247wallst.com
Decision brief

The 30-second read

$MKLNeutralLow
01

Why it matters

Provides a qualitative assessment without new quantitative triggers.

02

Market read

Primarily an opinion piece; limited immediate trading relevance.

03

What to watch

Potential future buyback acceleration or venture performance could change outlook.

Relevance 4/10Novelty 2/10Timing: none

Background

The article compares Markel Group to Berkshire Hathaway following Warren Buffett's transition, focusing on historical metrics.

Company-level read

Ticker impact

$MKLNeutralLow confidence
Context

Article discusses Markel Group's underwriting ratios, buybacks and performance metrics, but provides no new primary disclosure.

Expected impact

Limited impact; price likely unchanged.

Evidence & confidence

The piece is a retrospective comparison with Berkshire Hathaway, lacking fresh data or events.

Market effects

Sector

None significant; discussion of insurance sector performance only.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Markel may still offer value despite underperformance versus Berkshire.

Key entities

  • company
    Markel Group

    Insurance and investment holding company discussed as a Berkshire analogue.

  • company
    Berkshire Hathaway

    Reference point for comparison; not a primary subject.

Read at source← All news

Related articles

SEP 8
$MKLMed

Winners And Losers Of Q2: Markel Group (NYSE:MKL) Vs The Rest Of The Property & Casualty Insurance Stocks

Markel Group (MKL) reported flat Q2 revenue ($4.02B) beating estimates by 1.1% but missed EPS and book value per share. Essent Group (ESNT) saw revenue rise 13.6% ($362.7M), beating estimates by 9.7%. Radian Group (RDN) revenue up 95.7% ($580.7M) but missed EPS. Kinsale Capital (KNSL) revenue up 16.8% ($548.5M), beating estimates by 14.9%. The Hanover (THG) revenue up 4% ($1.72B) but missed estimates by 0.5%.

tradingview.com3 min
AUG 5
$MKLMed

Read Analyst Questions From Markel Group’s Q2 Earnings Call

Markel Group’s Q2 results triggered a negative market reaction as adjusted profit missed consensus despite revenue meeting expectations. The company attributed the shortfall to a $205 million reserve charge tied to a unique credit loss in its State National business. Revenue was $4.02B vs $3.97B expected, while adjusted EPS was $19.79 vs $30.57 expected.

financialcontent.com4 min
JUL 29
$MKLMed

Markel Group (NYSE:MKL) Posts Better

Markel Group (NYSE:MKL) reported Q2 2026 revenue of $4.02 billion, flat year over year but 1.2% above Wall Street estimates. GAAP EPS was $92.76, 13.9% above consensus. CEO Tom Gayner cited improved underwriting and strong cash flow, with capital allocation including share repurchases. The stock fell 1.2% to $1,990 after results.

financialcontent.com5 min
OCT 24
$CMPXHighAI 8/10

A bile duct cancer trial found 56% lower risk of progression or death with a drug combination.

Compass Therapeutics (CMPX) reported positive results from the COMPANION-002 trial of tovecimig in combination with paclitaxel for advanced biliary tract cancer. The study met primary and key secondary endpoints, showing a 56% reduction in disease progression or death risk. The drug demonstrated durable responses and improved disease control rates. The safety profile was consistent with prior studies.

stocktitan.net2 min
OCT 24
$BAMed

Boeing 777F production reportedly halted for nearly two months by supplier dispute

Boeing 777F production halted for nearly two months due to a dispute with supplier Vaero over wing components, costing Boeing up to $6.5M per day. The 777F has 38 unfilled orders, with a backlog of about 31 aircraft. The FAA extended production through 2030, allowing up to 35 additional 777Fs. Boeing delivered 21 777Fs in 2026, with demand continuing despite the transition to the 777-8F.

airdatanews.com3 min